Transrectal High-Intensity Focused Ultrasound Devices: A Critical Appraisal of the Available Evidence

[Guest guest]

Wednesday, 20 February 2008

Department

of Urology, Academic Medical Center,

University of Amsterdam,

The Netherlands.

Developments

in the technology applied to the field of minimally invasive surgery have led

to the exploration of high-intensity focused ultrasound (HIFU) for the treatment

of localized prostate cancer. Extensive research and continuous evolution have

resulted in two commercially available HIFU devices: the Ablatherm(®) and the

Sonablate500(®). These devices are conceptually the same; however, specific

technical differences exist. This paper reviews the clinical outcomes obtained

with these devices, evaluates the quality of the evidence from the individual

trials, and provides the results of a head-to-head comparison in terms of

oncologic outcomes and complication rates.

Written

by

Tsakiris P, Thüroff S, de la Rosette J, Chaussy C.

Reference

J

Endourol. 2008 Jan 22. Epub ahead of print.

doi:10.1089/end.2007.9849

PubMed

Abstract

PMID:18211209